Why It Matters
A federal judge in Texas has temporarily paused a high-stakes lawsuit challenging the Food and Drug Administration’s approval of mifepristone, an abortion medication. The decision delays legal action until after the upcoming midterm elections, creating a significant procedural pause in a national debate over reproductive healthcare access and federal regulatory authority.
What Happened
U.S. Chief District Judge Reed O’Connor, a former appointee of President George W. Bush, issued an order staying proceedings in the case brought by Republican attorneys general from Florida and Texas. As first reported by idahocapitalsun.com, the lawsuit seeks to revoke the FDA’s initial 2000 approval of mifepristone and subsequent regulatory decisions that expanded patient access to the drug. The judges’ stay means no further hearings will occur until at least December 1.
The Florida and Texas attorneys general filed their original complaint in December of last year, citing the federal Comstock Act. This 150-year-old anti-obscenity statute prohibits sending materials that could induce abortion through the mail, though it has not been enforced for many decades. The state officials argue the FDA violated this long-dormant law by approving and maintaining access to the medication.
Danco Laboratories and GenBioPro, manufacturers involved in mifepristone production, intervened as defendants in April after filing a motion to dismiss. Judge O’Connor denied that motion but agreed to the FDA’s request for a stay to allow the agency to complete an ongoing safety review. The FDA began this study in June and has announced a six-month timeline for completion.
By the Numbers
150 years old — federal Comstock Act cited by Texas and Florida
2000 — year of FDA’s initial mifepristone approval
June — month FDA began safety study
6 months — estimated completion time for FDA safety study
10 weeks’ gestation — timeframe for mifepristone use to terminate pregnancy
7 weeks’ gestation — pre-2016 approval limit
3 in-person office visits — pre-2016 requirement
December (year prior) — filing date of Florida and Texas lawsuit
April — month Danco Laboratories and GenBioPro intervened as defendants
Sept. 9 — date of 5th U.S. Circuit Court of Appeals oral arguments
Dec. 1 — earliest hearing date for paused case
2016 — year regulations changed regarding mifepristone access
2023 — year FDA reaffirmed mifepristone safety and effectiveness
Zoom Out
The Texas pause occurs alongside other federal litigation targeting mifepristone regulations nationwide. Three separate lawsuits are currently pending in federal courts, each seeking to modify or restrict how the medication is prescribed and dispensed across the United States.
In a parallel development, the 5th U.S. Circuit Court of Appeals will hear oral arguments on September 9 regarding a Louisiana case. That lawsuit challenges FDA rules allowing mifepristone to be dispensed without an in-person visit. Additionally, attorneys general from Missouri, Idaho, and Kansas have asked a federal judge in Missouri to roll back current regulations to pre-2016 standards. Before 2016, the drug was approved only for use before seven weeks of gestation and required three in-person office visits.
The FDA reaffirmed the safety and effectiveness of mifepristone in 2023. GenBioPro CEO Evan Masingill addressed the ongoing regulatory scrutiny in a public statement: “We expect the FDA’s review of mifepristone to not contradict the decision they made in 2023 that reaffirmed our product is safe and effective.” He added, “GenBioPro will continue to use all legal and regulatory tools available to ensure Americans’ access to reproductive care.”, as first reported by the Idaho Capital Sun
What’s Next
The immediate legal focus shifts to the FDA’s six-month safety study initiated in June. Once that review concludes, the Texas court may resume proceedings on whether the 2000 approval and subsequent access expansions violate federal law. The December 1 deadline establishes the earliest possible date for further judicial action in the Florida-Texas lawsuit, pushing any substantive rulings well into the post-election period.